Johannes Schetelig

Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study

Stephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig et al. · The Lancet Oncology · 2016 · 783 citations · Full text

Hematological Malignancy, Lymphoid Neoplasia, Medicine +7

Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial

Christoph Röllig, Hubert Serve, Andreas Hüttmann et al. · The Lancet Oncology · 2015 · 395 citations · Full text

Sorafenib Versus Placebo, Hematological Malignancy, Oncology +9

Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial

Uwe Platzbecker, Martin Wermke, J. Radke et al. · Leukemia · 2011 · 391 citations · Full text

Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus

Peter Dreger, Paolo Corradini, Eva Kimby et al. · Leukemia · 2006 · 381 citations

Cell Therapy, Transplantation, Marrow Transplantation +9

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial

Uwe Platzbecker, Jan Moritz Middeke, Katja Sockel et al. · The Lancet Oncology · 2018 · 341 citations

Hematological Malignancy, Oncology, Mixed-phenotype Acute Leukemia +10